Experts recommend earlier screening as breast cancer rates rise in younger women
UC professor and breast radiologist speaks with WLWT
As more people are being diagnosed with breast cancer at earlier ages, the U.S. Preventive Services Task Force lowered the screening age from 50 years old to 40 this year.
The University of Cincinnati's Ann Brown, MD, told WLWT early detection remains the best prevention.
"Early detection makes such a difference when we're dealing with breast cancer," said Brown, associate professor of radiology at the UC College of Medicine and a UC Health breast radiologist. "We know that it leads to better outcomes in terms of survival, but also better treatment options."
A mammogram is the most accurate way to detect the disease, Brown said.
"Our number one tool against breast cancer is screening mammography, especially with the latest 3D technology," Brown said. "That's why we're recommending screening every year at least starting at age 40. And if you have additional risk factors, you may need to start screening earlier, and with an additional test coupled with the mammogram like a breast MRI."
Featured image at top: A woman receives a mammogram. Photo/Rhoda Baer, National Cancer Institute via Unsplash
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.